IN2013MU02905A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02905A
IN2013MU02905A IN2905MU2013A IN2013MU02905A IN 2013MU02905 A IN2013MU02905 A IN 2013MU02905A IN 2905MU2013 A IN2905MU2013 A IN 2905MU2013A IN 2013MU02905 A IN2013MU02905 A IN 2013MU02905A
Authority
IN
India
Prior art keywords
preparation
improved process
relates
ethoxy
phenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Shri Prakash Dhar Dwivedi
Ramesh Chandra Singh
Jagdish Maganlal Patel
Vikas Patel
Vishwadeepak Rama Pati Tripathi
Pranav Jitendra Gangwar
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2905MU2013 priority Critical patent/IN2013MU02905A/en
Priority to US14/916,402 priority patent/US10112898B2/en
Priority to PCT/IN2014/000584 priority patent/WO2015033357A2/en
Publication of IN2013MU02905A publication Critical patent/IN2013MU02905A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2905MU2013 2013-09-06 2014-09-05 IN2013MU02905A (he)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IN2905MU2013 IN2013MU02905A (he) 2013-09-06 2014-09-05
US14/916,402 US10112898B2 (en) 2013-09-06 2014-09-05 Process for the preparation of saroglitazar pharmaceutical salts
PCT/IN2014/000584 WO2015033357A2 (en) 2013-09-06 2014-09-05 An improved process for the preparation of pyrrole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2905MU2013 IN2013MU02905A (he) 2013-09-06 2014-09-05

Publications (1)

Publication Number Publication Date
IN2013MU02905A true IN2013MU02905A (he) 2015-07-03

Family

ID=52023583

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2905MU2013 IN2013MU02905A (he) 2013-09-06 2014-09-05

Country Status (3)

Country Link
US (1) US10112898B2 (he)
IN (1) IN2013MU02905A (he)
WO (1) WO2015033357A2 (he)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2569248T3 (es) 2011-01-31 2016-05-09 Cadila Healthcare Limited Tratamiento para la lipodistrofia
MX346943B (es) 2013-04-22 2017-04-06 Cadila Healthcare Ltd Una nueva composición para esteatosis hepática no alcohólica (nafld).
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (he) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (he) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
US20220169603A1 (en) * 2019-03-11 2022-06-02 Cadila Healthcare Ltd. Novel salts, crystalline forms and premix of hypolipidemic agent
US20220023262A1 (en) * 2020-07-24 2022-01-27 Cadila Healthcare Limited Composition comprising high purity pyrrole derivative and method for preparation thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
DE69331010D1 (de) 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
KR100380875B1 (ko) 1995-04-28 2003-10-10 다이이찌 세이야꾸 가부시기가이샤 펜타사이클릭화합물
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
PL341795A1 (en) 1998-05-27 2001-05-07 Reddy Research Foundation Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DK1250323T3 (da) 2000-01-19 2014-02-03 Cadila Healthcare Ltd Forbindelser med hypolipidemiske og hypokolesterolemiske virkninger, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
US6514995B1 (en) 2000-09-25 2003-02-04 Advanced Research And Technology Institute, Inc. Enediyne compounds and methods related thereto
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20070051626A1 (en) 2003-09-26 2007-03-08 Chiho Itou Cataphoresis apparatus cataphoresis method, and detection method for organism-related material using the apparatus and the method
EA013427B1 (ru) 2004-03-15 2010-04-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы дипептидилпептидазы
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
PT2504005E (pt) 2009-11-26 2014-01-10 Genfit Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
US8501816B2 (en) 2010-10-12 2013-08-06 Cerecor, Inc. Antitussive compositions comprising memantine
ES2569248T3 (es) 2011-01-31 2016-05-09 Cadila Healthcare Limited Tratamiento para la lipodistrofia
MX346943B (es) 2013-04-22 2017-04-06 Cadila Healthcare Ltd Una nueva composición para esteatosis hepática no alcohólica (nafld).
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (he) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (he) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
IN2013MU02905A (he) 2013-09-06 2015-07-03 Cadila Healthcare Ltd

Also Published As

Publication number Publication date
WO2015033357A2 (en) 2015-03-12
US10112898B2 (en) 2018-10-30
US20160194280A1 (en) 2016-07-07
WO2015033357A3 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
IN2013MU02905A (he)
PH12020551628A1 (en) A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
HK1207077A1 (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol- 3-yl]-4-(4-methyl piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)- benzamide n-[5-(35--)-1h--3-]-4-(4---1-)-2-(- -4-)-
MY181898A (en) Heterocyclic compounds and uses thereof
MY150542A (en) Cmet inhibitors
MX2012004114A (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
CL2014001765A1 (es) Proceso para la fabricacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina.
TN2011000673A1 (en) Bace inhibitors
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX2010012298A (es) Activadores de glucocinasa.
EA200900441A1 (ru) Способы и интермедиаты для получения ингибиторов интегразы
UY34480A (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos, composiciones y métodos para controlar malezas.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX353578B (es) Dihidrodiazpinocarbazolonas tetra o penta-ciclicas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
HUE041725T2 (hu) (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EP3666770A4 (en) NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS
CL2011003009A1 (es) Proceso de preparacion de compuestos derivados de 4-fenil-3,5-(tio)piranodionas; compuesto intermediario; y preparacion de dicho intermediario.
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX364207B (es) Inhibidores de agrecanasa.
MX2011006560A (es) Derivados heterociclicos fucionados con oxadiazola utiles para el tratamiento de esclerosis multiple.
IN2013MU03862A (he)
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
WO2013175499A3 (en) Process for the preparation of 5-(4-[4-(5-cyano-1 h-indol-3-yl)butyl]piperazin-1 -yl)benzofuran-2-carboxamide and intermediates thereof, polymorphic forms thereof